Luca Issi
Stock Analyst at RBC Capital
(3.54)
# 862
Out of 5,180 analysts
221
Total ratings
47.86%
Success rate
4.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Outperform | $11 → $35 | $16.89 | +107.22% | 8 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $9 → $15 | $13.27 | +13.04% | 8 | Mar 3, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $250 → $275 | $228.24 | +20.49% | 5 | Mar 3, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $925 → $890 | $743.12 | +19.77% | 4 | Feb 27, 2026 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $22 → $26 | $24.22 | +7.35% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Sector Perform | $25 → $30 | $50.03 | -40.04% | 19 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $500 → $465 | $328.73 | +41.45% | 29 | Jan 20, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $82 → $95 | $75.13 | +26.45% | 11 | Dec 17, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $62.92 | +27.15% | 11 | Dec 11, 2025 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $9 → $27 | $6.83 | +295.31% | 6 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $10 | $7.48 | +33.69% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $57 → $28 | $34.19 | -18.10% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $85 → $8 | $12.65 | -36.76% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $42 → $50 | $48.81 | +2.44% | 15 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $19 | $8.63 | +120.16% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $18.10 | +65.75% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.56 | +290.63% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $40.39 | -55.43% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $5.67 | +252.73% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.26 | +668.94% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $8.33 | +104.08% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $9.09 | +43.01% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $9.87 | +254.61% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $57.24 | +22.29% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $50.03 | +13.93% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.61 | +53.26% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $21.42 | +259.48% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.99 | +603.52% | 5 | Aug 7, 2024 |
uniQure
Mar 9, 2026
Upgrades: Outperform
Price Target: $11 → $35
Current: $16.89
Upside: +107.22%
Intellia Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $9 → $15
Current: $13.27
Upside: +13.04%
Ascendis Pharma
Mar 3, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $228.24
Upside: +20.49%
argenx SE
Feb 27, 2026
Maintains: Outperform
Price Target: $925 → $890
Current: $743.12
Upside: +19.77%
Beam Therapeutics
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $26
Current: $24.22
Upside: +7.35%
Moderna
Feb 17, 2026
Maintains: Sector Perform
Price Target: $25 → $30
Current: $50.03
Upside: -40.04%
Alnylam Pharmaceuticals
Jan 20, 2026
Maintains: Outperform
Price Target: $500 → $465
Current: $328.73
Upside: +41.45%
Ionis Pharmaceuticals
Dec 17, 2025
Maintains: Outperform
Price Target: $82 → $95
Current: $75.13
Upside: +26.45%
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $62.92
Upside: +27.15%
Wave Life Sciences
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $6.83
Upside: +295.31%
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $7.48
Upside: +33.69%
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $34.19
Upside: -18.10%
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $12.65
Upside: -36.76%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $48.81
Upside: +2.44%
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $8.63
Upside: +120.16%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $18.10
Upside: +65.75%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $2.56
Upside: +290.63%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $40.39
Upside: -55.43%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $5.67
Upside: +252.73%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.26
Upside: +668.94%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $8.33
Upside: +104.08%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $9.09
Upside: +43.01%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $9.87
Upside: +254.61%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $57.24
Upside: +22.29%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $50.03
Upside: +13.93%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.61
Upside: +53.26%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $21.42
Upside: +259.48%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.99
Upside: +603.52%